Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether anti‐CD52 mAb maintenance therapy changes progression‐free survival compared with observation (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy probably leads to lower progression‐free survival compared with observation (moderate certainty).
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment discontinuation compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).